These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30418122)

  • 41. Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis.
    Burmester GR; Durez P; Shestakova G; Genovese MC; Schulze-Koops H; Li Y; Wang YA; Lewitzky S; Koroleva I; Berneis AA; Lee DM; Hueber W
    Rheumatology (Oxford); 2016 Jan; 55(1):49-55. PubMed ID: 26268815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis.
    Wang X; Ma C; Li P; Zhao F; Bi L
    Clin Rheumatol; 2017 Jun; 36(6):1369-1377. PubMed ID: 28474138
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum concentration of dickkopf-related protein 1 (DKK1) in psoriatic arthritis in the context of bone remodelling.
    Biedroń G; Czepiel M; Siedlar M; Korkosz M
    Rheumatol Int; 2023 Dec; 43(12):2175-2183. PubMed ID: 37750896
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum soluble bone turnover biomarkers in psoriatic arthritis and psoriatic spondyloarthropathy.
    Jadon DR; Nightingale AL; McHugh NJ; Lindsay MA; Korendowych E; Sengupta R
    J Rheumatol; 2015 Jan; 42(1):21-30. PubMed ID: 25362660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Secukinumab: a promising therapeutic option in spondyloarthritis.
    Maldonado-Ficco H; Perez-Alamino R; Maldonado-Cocco JA
    Clin Rheumatol; 2016 Sep; 35(9):2151-61. PubMed ID: 27437696
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1).
    Strand V; Mease P; Gossec L; Elkayam O; van den Bosch F; Zuazo J; Pricop L; Mpofu S;
    Ann Rheum Dis; 2017 Jan; 76(1):203-207. PubMed ID: 27169431
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High serum levels of sclerostin and Dickkopf-1 are associated with acute ischaemic stroke.
    He XW; Wang E; Bao YY; Wang F; Zhu M; Hu XF; Jin XP
    Atherosclerosis; 2016 Oct; 253():22-28. PubMed ID: 27573735
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of serum Dkk-1 levels with β-catenin in patients with postmenopausal osteoporosis.
    Tian J; Xu XJ; Shen L; Yang YP; Zhu R; Shuai B; Zhu XW; Li CG; Ma C; Lv L
    J Huazhong Univ Sci Technolog Med Sci; 2015 Apr; 35(2):212-218. PubMed ID: 25877354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study.
    Kavanaugh A; Mease PJ; Reimold AM; Tahir H; Rech J; Hall S; Geusens P; Wang Z; Pricop L; Mpofu S;
    Arthritis Care Res (Hoboken); 2017 Mar; 69(3):347-355. PubMed ID: 27696786
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association between serum and synovial fluid Dickkopf-1 levels with radiographic severity in primary knee osteoarthritis patients.
    Theologis T; Efstathopoulos N; Nikolaou V; Charikopoulos I; Papapavlos I; Kokkoris P; Papatheodorou A; Nasiri-Ansari N; Kassi E
    Clin Rheumatol; 2017 Aug; 36(8):1865-1872. PubMed ID: 28451870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dickkopf-Related Protein 1 (DKK-1) as a Possible Link between Bone Erosions and Increased Carotid Intima-Media Thickness in Psoriatic Arthritis: An Ultrasound Study.
    Biță CE; Dinescu ȘC; Riza AL; Ciurea PL; Mușetescu AE; Marinescu D; Dumitrașcu RM; Șuiu LI; Ionescu RA; Popoviciu HV; Vreju FA
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834418
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The assessment of the drug retention rate of secukinumab in patients with psoriatic arthritis in a real-life multicentre cohort.
    Ruscitti P; Pantano I; Perrotta FM; Celletti E; Volpe P; Ciliento MS; Marino V; Raimondi M; Gaggiano E; Mauro D; Cataldi G; Italiano N; Di Muzio C; Navarini L; Zicolella R; Gabini M; Cipollone F; Lubrano E; Giacomelli R; Ciccia F; Cipriani P
    Clin Exp Rheumatol; 2024 Jan; 42(1):69-76. PubMed ID: 37497733
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
    J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beyond anti-TNF-α agents in psoriatic arthritis.
    Spadaro A; Lubrano E
    Expert Rev Clin Immunol; 2013 Jun; 9(6):507-9. PubMed ID: 23730881
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.
    van der Heijde D; Landewé RB; Mease PJ; McInnes IB; Conaghan PG; Pricop L; Ligozio G; Richards HB; Mpofu S
    Arthritis Rheumatol; 2016 Aug; 68(8):1914-21. PubMed ID: 27014997
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Cross-Sectional Study to Assess the Modulation of Wnt Inhibitors following Anti-Epileptic Drug Therapy and their Correlation with Vitamin D and Receptor Activator of Nuclear Factor κ B Ligand in Indian Women with Epilepsy.
    Parveen B; Tripathi M; Vohora D
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):271-276. PubMed ID: 29504704
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Secukinumab: first global approval.
    Sanford M; McKeage K
    Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study.
    Kavanaugh A; McInnes IB; Mease PJ; Hall S; Chinoy H; Kivitz AJ; Wang Z; Mpofu S
    J Rheumatol; 2016 Sep; 43(9):1713-7. PubMed ID: 27307536
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Secukinumab (AIN-457) for the treatment of Psoriasis.
    Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
    Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.